The Shingles Vaccine’s Unexpected Dementia Clue

Basic Applied Science
14 followers
2 Video Views·Nov 14, 2026
Research suggests that the shingles vaccine may be associated with a lower risk of dementia. However, this finding does not prove that the vaccine prevents the condition; further research is needed to confirm its protective efficacy in humans.
AI Generated·May contain errors
Two people born one week apart.
In Wales, that week decided whether they could get a shingles
vaccine through the public program.
The younger one was eligible. The older one was just too old
and never would be. Among people just either side
of that birthday line, almost none on the older
side got the shot. Nearly half on the younger side did.
Seven years later, researchers checked
who had developed dementia. I'm Dr. Male, a neurologist.
Here's what that birthday revealed.
People who choose vaccination may also get more preventive care.
So if they stay healthier, what deserves the credit?
The birthday rule worked more like a lottery.
Access depended on when you were born.
Researchers compared people very close to the line
with similar health and circumstances.
It wasn't a randomized trial,
but it made the comparison much harder to dismiss.
Seven years later, dementia diagnoses showed a difference too.
Using that birthday comparison, the researchers estimated
that vaccination led to about 3.5 fewer new dementia diagnoses
per 100 people, about 20% lower in relative terms.
The estimated benefit was larger in women.
But could something else explain the result?
First, shingles fell, as you'd expect if the vaccine was doing its job.
Then the researchers looked for other changes.
They found no clear effect on other common diseases
and no rise in other vaccines or
checkups on the eligible side.
And no other Welsh program used that same birthday as its cutoff.
Those checks strengthened the case. Next came a different test.
Would it happen somewhere else?
Australia had its own birthday cut-off for a free shingles vaccine.
The same Stanford-led research group examined that program.
Different country, different health system.
Another chance to test the idea.
Again, people just on the eligible side had
fewer new dementia diagnoses during follow-up.
Then the team went back to Wales with a stranger question.
What about people already living with dementia when the program began?
Over 9 years, those on the eligible side had fewer deaths recorded
as due to dementia.
That raises the possibility of slowing the disease course.
It doesn't show that memory declined more slowly.
The outcome came from death certificates, not memory tests.
How could a vaccine against shingles affect the brain?
The chickenpox virus stays in nerve cells after the infection.
When it reactivates, it can also inflame blood vessels.
Studies find a higher stroke rate after shingles,
especially in the early months and when the eye region is involved.
And strokes, large and small, can contribute to dementia.
Broader effects on the immune system are another possibility.
The vaccine studies haven't established the mechanism.
And there's a practical question. What about the vaccine offered today?
Wales and Australia studied the older, live vaccine.
In the United States, we now use Shingrix, which is non-live.
A large US study compared the two.
Shingrix was associated with more time without
a dementia diagnosis during follow-up.
That adds another clue.
Though differences between the groups could still help explain it.
So how seriously do I take this?
Seriously.
Bodad.
Because the birthday studies fix a major weakness
in ordinary vaccine comparisons.
But they don't prove that Shingrix prevents dementia,
and they can't promise protection
for any one person. For the decision in front of you,
there's a benefit we know much more about.
About one in three people in the United States will get shingles.
It can leave nerve pain lasting months.
In trials, Shingrix was more than 90% effective against shingles
in adults 50 and older with
healthy immune systems.
The CDC recommends two doses for adults 50 and older and for adults 19
and older with immune systems weakened by disease
or treatment. A sore arm,
Tiredness and aches are common and usually last a few days.
A rare condition causing serious weakness,
Guillain-Barre syndrome, has been linked to
a few additional cases per million doses in adults 65
and older during the six weeks after vaccination.
Discuss previous serious vaccine reactions with your clinician.
A severe allergy to a previous dose or vaccine ingredient rules it out.
If you have shingles now, wait until it resolves.
In Wales, a birthday decided who could get the shot.
In the United States, there's no birthday lottery.
If you're 50 or older, or 19 to 49 with a weakened immune system,
ask your clinician or pharmacist whether you're due.
Preventing shingles is the established reason to vaccinate.
Whether it also protects the brain is still being tested.
But a possible bonus, not a promise.
For clear explanations of what brain health research means for you,
subscribe to NeuroClarified.
